Novartis AG’s most advanced nephrology pipeline asset, iptacopan (LNP023), has proven its mettle in a Phase II study in one of its potential indications, C3 glomerulopathy (C3G).
Novartis Advances Novel Kidney Disease Therapy Iptacopan
Data Suggest Promise For Lead Nephrology Asset
Phase II results look good for one of the first-in-class product’s potential indications, C3 glomerulopathy. The product was highlighted late last year as an up-and-coming pipeline asset.
